Literature DB >> 22286752

Susceptibility to vaccinia virus infection and spread in mice is determined by age at infection, allergen sensitization and mast cell status.

Joanne Domenico1, Joseph J Lucas, Mayumi Fujita, Erwin W Gelfand.   

Abstract

BACKGROUND: Patients, especially young children, with atopic dermatitis are at an increased risk of developing eczema vaccinatum, a severe reaction to the smallpox vaccine, either through direct vaccination or indirect contact with a person recently vaccinated.
METHODS: Using a mouse model of infection, the severity of vaccinia-induced lesions was assessed from their appearance and viral DNA content. The response to vaccinia inoculation was assessed in young and adult mice, allergen-sensitized mice, and in mast cell-deficient mice.
RESULTS: Young age, sensitization to an allergen prior to infection, and a mast cell deficit, accomplished by using mast cell-deficient mice, resulted in more severe viral lesions at the site of inoculation, according to lesion appearance and viral DNA content. All three factors combined demonstrated maximal susceptibility, characterized by the severity of primary lesions and the development of secondary (satellite) lesions, as occurs in eczema vaccinatum in humans. Resistance to the appearance of satellite lesions could be restored by adoptive transfer of bone marrow-derived mast cells from either wild-type or cathelicidin-related antimicrobial peptide-deficient mice. Primary lesions were more severe following the latter transfer, indicating that cathelicidin-related antimicrobial peptide does contribute to the protective activity of mast cells against infection.
CONCLUSIONS: The combination of young age, allergen sensitization and a mast cell deficit resulted in the most severe lesions, including satellite lesions. Understanding the factors determining the relative resistance/sensitivity to vaccinia virus will aid in the development of strategies for preventing and treating adverse reactions which can occur after smallpox vaccination.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286752      PMCID: PMC3291886          DOI: 10.1159/000330647

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  43 in total

1.  Endogenous antimicrobial peptides and skin infections in atopic dermatitis.

Authors:  Peck Y Ong; Takaaki Ohtake; Corinne Brandt; Ian Strickland; Mark Boguniewicz; Tomas Ganz; Richard L Gallo; Donald Y M Leung
Journal:  N Engl J Med       Date:  2002-10-10       Impact factor: 91.245

2.  The prevalence of atopic dermatitis in Oregon schoolchildren.

Authors:  D Laughter; J A Istvan; S J Tofte; J M Hanifin
Journal:  J Am Acad Dermatol       Date:  2000-10       Impact factor: 11.527

3.  Mice lacking the transcription factor RelB develop T cell-dependent skin lesions similar to human atopic dermatitis.

Authors:  D Barton; H HogenEsch; F Weih
Journal:  Eur J Immunol       Date:  2000-08       Impact factor: 5.532

4.  Smallpox vaccination: Risk considerations for patients with atopic dermatitis.

Authors:  Renata J M Engler; Julie Kenner; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2002-09       Impact factor: 10.793

5.  Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response.

Authors:  Michiko K Oyoshi; Abdallah Elkhal; Lalit Kumar; Jordan E Scott; Suresh Koduru; Rui He; Donald Y M Leung; Michael D Howell; Hans C Oettgen; George F Murphy; Raif S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

Review 6.  Mast cells in atopic dermatitis.

Authors:  Toshiaki Kawakami; Tomoaki Ando; Miho Kimura; Bridget S Wilson; Yuko Kawakami
Journal:  Curr Opin Immunol       Date:  2009-10-14       Impact factor: 7.486

7.  Phenotype of atopic dermatitis subjects with a history of eczema herpeticum.

Authors:  Lisa A Beck; Mark Boguniewicz; Tissa Hata; Lynda C Schneider; Jon Hanifin; Rich Gallo; Amy S Paller; Susi Lieff; Jamie Reese; Daniel Zaccaro; Henry Milgrom; Kathleen C Barnes; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2009-06-27       Impact factor: 10.793

8.  Enhanced expression of the antimicrobial peptide LL-37 in lesional skin of adults with atopic eczema.

Authors:  N Ballardini; C Johansson; G Lilja; M Lindh; Y Linde; A Scheynius; B Agerberth
Journal:  Br J Dermatol       Date:  2009-03-20       Impact factor: 9.302

9.  Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury.

Authors:  Jürgen Harder; Stefanie Dressel; Maike Wittersheim; Jesko Cordes; Ulf Meyer-Hoffert; Ulrich Mrowietz; Regina Fölster-Holst; Ehrhard Proksch; Jens-Michael Schröder; Thomas Schwarz; Regine Gläser
Journal:  J Invest Dermatol       Date:  2010-01-28       Impact factor: 8.551

Review 10.  Recent insights into atopic dermatitis and implications for management of infectious complications.

Authors:  Mark Boguniewicz; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2010-01       Impact factor: 10.793

View more
  9 in total

1.  Both CD8+ and CD4+ T Cells Contribute to Corneal Clouding and Viral Clearance following Vaccinia Virus Infection in C57BL/6 Mice.

Authors:  I V Larsen; H Clausius; A W Kolb; C R Brandt
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

Review 2.  Mast Cells Meet Cytomegalovirus: A New Example of Protective Mast Cell Involvement in an Infectious Disease.

Authors:  Sara Becker; Matthias J Reddehase; Niels A Lemmermann
Journal:  Cells       Date:  2022-04-21       Impact factor: 7.666

3.  Age at Vaccination May Influence Response to Sylvatic Plague Vaccine (SPV) in Gunnison's Prairie Dogs (Cynomys gunnisoni).

Authors:  Tonie E Rocke; Dan Tripp; Faye Lorenzsonn; Elizabeth Falendysz; Susan Smith; Judy Williamson; Rachel Abbott
Journal:  Ecohealth       Date:  2015-01-15       Impact factor: 4.464

Review 4.  Mast cells and influenza a virus: association with allergic responses and beyond.

Authors:  Amy C Graham; Rachel M Temple; Joshua J Obar
Journal:  Front Immunol       Date:  2015-05-18       Impact factor: 7.561

Review 5.  Mast Cell Responses to Viruses and Pathogen Products.

Authors:  Jean S Marshall; Liliana Portales-Cervantes; Edwin Leong
Journal:  Int J Mol Sci       Date:  2019-08-30       Impact factor: 5.923

Review 6.  Cationic host defense peptides; novel antimicrobial therapeutics against Category A pathogens and emerging infections.

Authors:  Fern Findlay; Lorna Proudfoot; Craig Stevens; Peter G Barlow
Journal:  Pathog Glob Health       Date:  2016-06-17       Impact factor: 2.894

7.  Impact of Sylvatic Plague Vaccine on Non-target Small Rodents in Grassland Ecosystems.

Authors:  Gebbiena M Bron; Katherine L D Richgels; Michael D Samuel; Julia E Poje; Faye Lorenzsonn; Jonathan P Matteson; Jesse T Boulerice; Jorge E Osorio; Tonie E Rocke
Journal:  Ecohealth       Date:  2018-05-09       Impact factor: 4.464

8.  Locally Produced IL-10 Limits Cutaneous Vaccinia Virus Spread.

Authors:  Stephanie S Cush; Glennys V Reynoso; Olena Kamenyeva; Jack R Bennink; Jonathan W Yewdell; Heather D Hickman
Journal:  PLoS Pathog       Date:  2016-03-18       Impact factor: 6.823

Review 9.  Divergent Mast Cell Responses Modulate Antiviral Immunity During Influenza Virus Infection.

Authors:  Ashleigh R Murphy-Schafer; Silke Paust
Journal:  Front Cell Infect Microbiol       Date:  2021-02-19       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.